Siddharth Ninan, MD
Neurology · Fairfax, VANPI 1285123372
Payments from drug & device makers
Across 48 payments — averaging $158.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$3K
- EMD Serono, Inc.$2K
- AstraZeneca$2K
- Teva Pharmaceuticals USA, Inc.$232
- Sanofi$224
- Novartis$172
- plus $682 from 12 others
What the payments were for
- Consulting fees$3,12041%
- Speaking & faculty fees$2,50033%
- Food & beverage$1,93125%
- Education$781%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 4 | $2,581 |
| EMD Serono, Inc. | 10 | $2,010 |
| AstraZeneca | 2 | $1,726 |
| Teva Pharmaceuticals USA, Inc. | 2 | $232 |
| Sanofi | 3 | $224 |
| Novartis | 7 | $172 |
| Genentech USA, Inc. | 4 | $170 |
| Biogen | 4 | $151 |
| Amgen | 1 | $91 |
| TG Therapeutics, Inc. | 2 | $69 |
| Banner Life Sciences, LLC | 2 | $47 |
| Mallinckrodt Hospital Products Inc. | 1 | $29 |
| Lilly USA, LLC | 1 | $25 |
| Argenx US, Inc. | 1 | $23 |
| Boston Scientific | 1 | $23 |
| Cycle Pharmaceuticals Inc | 1 | $22 |
| Vanda Pharmaceuticals Inc. | 1 | $18 |
| ANI Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ULTOMIRIS$1,720
- Austedo XR$119
- Mavenclad$115
- AJOVY$113
How this compares
$7,629 in reported general payments places this provider in the 65th percentile of 474 neurology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Memantine Hcl ErMemantine Hcl | 11 | $2,030 |
| Gabapentin | 86 | $1,527 |
| Oxcarbazepine | 21 | $1,255 |
| RizatriptanRizatriptan Benzoate | 20 | $903 |
| Baclofen | 12 | $766 |
| Donepezil Hcl | 60 | $665 |
| Memantine Hcl | 18 | $535 |
| Nortriptyline Hcl | 40 | $458 |
| Primidone | 36 | $432 |
| Tizanidine Hcl | 34 | $331 |
| Duloxetine Hcl | 26 | $327 |
| Levetiracetam | 11 | $301 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 20 | $234 |
| Atorvastatin Calcium | 21 | $188 |
| Methylprednisolone | 18 | $113 |
Paid to pharmacies, not to this prescriber.
Other neurology in Fairfax
- Rahul DaveFairfax$1M
- John RothrockFairfax$504K
- James SimsarianFairfax$173K
- Laura CinskiFairfax$124K
- Abigail LawlerFairfax$107K
- Michelle BetzVirginia Beach$3.3M
- Daniel CohenNorfolk$2.9M
- Heidi CraytonVienna$2.5M
- Ramsey FalconerAlexandria$2.4M
- Robert ShinCharlottesville$2.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.